Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

نویسندگان

  • Peter Abbink
  • Rafael A Larocca
  • Kittipos Visitsunthorn
  • Michael Boyd
  • Rafael A De La Barrera
  • Gregory D Gromowski
  • Marinela Kirilova
  • Rebecca Peterson
  • Zhenfeng Li
  • Ovini Nanayakkara
  • Ramya Nityanandam
  • Noe B Mercado
  • Erica N Borducchi
  • Abishek Chandrashekar
  • David Jetton
  • Shanell Mojta
  • Priya Gandhi
  • Jake LeSuer
  • Shreeya Khatiwada
  • Mark G Lewis
  • Kayvon Modjarrad
  • Richard G Jarman
  • Kenneth H Eckels
  • Stephen J Thomas
  • Nelson L Michael
  • Dan H Barouch
چکیده

An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-sp...

متن کامل

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

Preclinical studies of viral vector-based HIV-1 vaccine candidates have previously shown partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vector priming followed by purified envelope (Env) glycoprotein boosting. Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 ...

متن کامل

A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice

A DNA vaccine encoding prM and E protein has been shown to induce protection against Zika virus (ZIKV) infection in mice and monkeys. However, its effectiveness in humans remains undefined. Moreover, identification of which immune cell types are specifically infected in humans is unclear. We show that human myeloid cells and B cells are primary targets of ZIKV in humanized mice. We also show th...

متن کامل

Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.

A chimeric yellow fever (YF)-dengue serotype 2 (dengue 2) virus was constructed by replacing the premembrane and envelope genes of the YF 17D virus with those from dengue 2 virus strains of Southeast Asian genotype. The virus grew to high titers in Vero cells and, after passage 2, was used for immunogenicity and attenuation studies in rhesus monkeys. Subcutaneous immunization of naive rhesus mo...

متن کامل

مروری جامع بر عفونت ویروس زیکا

Zika virus is a mosquito-borne flavivirus that is becoming a new global threat. Currently, serologic (ELISA) and molecular (RT-PCR) testing make the diagnosis of Zika virus infection. There is no specific drug available for Zika virus infection, and treatment is supportive based on reducing symptoms of disease. Protection against mosquito bites is the most effective way to prevent the infection...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Science translational medicine

دوره 9 420  شماره 

صفحات  -

تاریخ انتشار 2017